Abstract:摘要 生物医学精准诊断对于疾病的有效治疗十分重要. 纳米基成像 造影剂具有灵敏度高、特异性强、生物相容性好等特点, 在生物医学 成像诊断中具有巨大的临床转化潜力. 目前, 尽管研究者们构筑了大量 的纳米基探针材料作为疾病诊断造影剂, 但纳米材料造影剂在临床转 化方面仍然面临极大的挑战. 这里我们主要概述了不同生物医学成像 类型的纳米基造影剂所面临的问题, 并针对这些难题提出了应对方案 和未来的研究重点, 最后对纳米基造影剂的临床转化前景进行了展望.
What problem does this paper attempt to address?
This paper discusses the application of nanomaterial-based imaging contrast agents in the diagnosis of common diseases such as cancer, cardiovascular and cerebrovascular diseases, and inflammatory diseases. Currently, these diseases are major health problems, and accurate clinical diagnostic techniques (such as magnetic resonance imaging MRI, ultrasound US, and X-ray computed tomography CT) are crucial for effective treatment. Contrast agents can enhance imaging clarity and provide biological information. Nano-contrast agents can achieve cellular and subcellular level localization due to their small size.
In recent years, the development of nanomaterial science has given rise to a series of nano-contrast agents with high sensitivity, selectivity, and targeting functions. Compared to traditional imaging agents, nano-contrast agents maintain structural and functional integrity in the body for a longer period of time, enhancing imaging persistence and accuracy. In addition, surface modification increases their affinity for specific biomolecules or tissues, improving the accuracy of target labeling and detection.
Despite success in basic research, nano-contrast agents still face significant challenges in clinical applications. The article lists the limitations of nano-contrast agents in imaging modes such as CT, MRI, fluorescence (FL), and positron emission tomography (PET), including low sensitivity, potential toxicity, and difficulties in large-scale production, and proposes corresponding solutions. For example, CT contrast agents need to improve permeability and targeting while reducing toxicity; MRI contrast agents require enhanced stability and targeting to prolong in vivo retention time; fluorescence contrast agents need to improve quantum efficiency and penetration depth; PET contrast agents need to focus on structural stability, biological safety, and radioactivity safety.
Overall, the paper aims to summarize the latest advances of nano-contrast agents in imaging of various chronic diseases, identify key issues in clinical translation, and propose possible solutions to overcome these problems, in order to accelerate the application of nano-contrast agents from the laboratory to the clinic.